Keywords: boeh, ingelheim, aptivus, hiv, gets, accelerated, approval
Boeh Ingelheim's Aptivus for HIV gets accelerated approval by FDA
Article | 04 July 2005
The US Food and Drug Administration has granted German drugmaker Boehringer Ingelheim accelerated approval of its anti-HIV drug Aptivus (tipranavir) ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Is failure to adopt business process management putting the pharma industry at risk?
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Pfizer to split-off remaining 80% interest in Zoetis
